

Curriculum Vitae

PERSONAL DATA

Name: Sandeep Vijan

EDUCATION

Sept. 1981- June 1985	Diploma, Athens High School, Troy, Michigan
Sept. 1985- May 1989	B.S., University of Michigan, Ann Arbor, Michigan
July 1988- May 1992	M.D., University of Michigan, Ann Arbor, Michigan
Sept. 1995- June 1997	M.S. in Clinical Research Design and Statistical Analysis University of Michigan School of Public Health and Rackham School of Graduate Studies, Ann Arbor, Michigan

POSTDOCTORAL TRAINING

June 1992- July 1995	Residency, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan
-------------------------	---

SENIOR POSTDOCTORAL TRAINING

None

ACADEMIC APPOINTMENTS

July 1995- June 1997	AHCPR Health Services Research Fellow, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan
July 1997- present	Investigator, Veterans' Administration Health Services Research and Development, Ann Arbor, Michigan
July 1997- June 1999	Lecturer, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan
July 1999- present	Assistant Professor, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan

ACADEMIC ADMINISTRATIVE APPOINTMENTS

July 1998- June 2001	Associate Director, Michigan Diabetes Research and Training Center, Modeling Core
-------------------------	--

CLINICAL/HOSPITAL APPOINTMENTS

July 1995- present	Staff Physician, Ann Arbor Veterans Administration Health System
-----------------------	---

July 1997- present	Staff Physician, University of Michigan Health System
-----------------------	---

CONSULTING POSITIONS

July 1998- management present	American College of Physicians, PIER module for the of type 2 diabetes
-------------------------------------	---

July 1999- present	American College of Physicians, treatment of cardiovascular risk factors in type 2 diabetes
-----------------------	--

November 2003- present	BMJ Clinical Evidence; Treatment of hypertension in type 2 diabetes
---------------------------	--

SCIENTIFIC AND RESEARCH ACTIVITIES

EDITORIAL BOARDS

Medical Care Research and Review

MANUSCRIPT REVIEW

Journal of General Internal Medicine
Annals of Internal Medicine
Journal of the American Medical Association
Archives of Internal Medicine
American Journal of Medicine
Medical Care
Diabetologia
Effective Clinical Practice
Diabetic Medicine
Diabetes Care
Gastroenterology

American Journal of Managed Care
Journal of the American College of Cardiology
American Journal of Gastroenterology
Breast Cancer Research

STUDY SECTIONS

Chair, Veterans Affairs Health Services Research & Development Scientific Review and Evaluation Board (2004-present)

Veterans Affairs Quality Enhancement Research Initiative (2001-2003)

RESEARCH EXPERIENCE

The Use of Inhaled Aminoglycosides in the Treatment of Nosocomial Pneumonia, Senior Research Project, April 1995

Oropharyngeal Bacterial Colonization in Nursing Home Patients, 1989

Research Fellow, Center for Practice Management and Outcomes Research, Ann Arbor Veterans Administration Medical Center, 1995-present.

GRANT SUPPORT

Current

1. Consultant, "Quality Enhancement Research Initiative, Diabetes." Veterans Administration DIB 98-001, direct costs \$200,000 annually (renewable). Rodney A. Hayward, PI. 10% effort for each year (most recent funding renewal 10/1/2004-9/30/2005).
2. Co-Investigator, "An Evaluation of a Coordinated Proactive Diabetes Eye Care Program". Veterans Administration QUERI; direct costs \$499,595 over 2 years. 10% effort. Steven Bernstein, PI. Funding date 1/2/2004.
3. Principal investigator, "The cost-effectiveness of genetic screening for colon cancer". National Institutes of Health, National Cancer Institute. Direct costs \$450,000 over 3 years. 25% effort per year. Grant 1 R01 CA106782-01. Funded on first submission (percentile score = 9.5). Funding dates 6/5/2004-5/31/2007
4. Principal investigator, "Measuring the value of diabetes disease management." Agency for Healthcare Research and Quality. 15% effort; subcontract through Joe Selby, MD, MPH, Kaiser Permanente Northern California. Funding dates 1/1/2004-4/1/2005.

Pending

1. Co-investigator, "The Effect of Patient Adherence on the Cost-Effectiveness of Screening for Colorectal Neoplasia." National Institutes of Health, National Cancer Institute. Direct costs \$1,100,000 over 3.5 years; 15% effort per year. Submitted July 1, 2004.
2. Co-investigator, "The Effect of Patient Adherence on the Cost-Effectiveness of Screening for Colorectal Neoplasia." VA HSR&D. 15% effort per year. Submitted June 15, 2004.
3. Co-investigator, "Insulin Treatment Variation in Southwestern Diabetics: Therapeutic Decision-making." VA HSR&D; 5% effort per year. Submitted June 15, 2004.

Recent

1. Principal Investigator, Mentored Career Development Award. "Diabetes Care: Optimizing Quality, Minimizing Risk. Veterans Administration. 100% salary support for 3 years (funding date 1/1/2001).
2. Principal Investigator, "Patient Preferences and the Care of Diabetes." Veterans Administration HSR&D IIR 970781, direct costs \$284,380. 20% effort for 2.5 years (funding dates 9/1/98-3/1/01).
3. Associate Director, Modeling Core, Michigan Diabetes Research and Training Center. NIH (NIDDK) P60-DK20572. 5% effort for 5 years.
4. Principal Investigator, "The impact of chronic diseases on work-force participation". Social Security Administration/Michigan Retirement Research Center grant UM01-11, direct costs \$100,000. 10% effort for 1 year (funding date 10/1/2000, effort donated as of 1/1/01).
5. Co-Investigator, "Developing Electronic Communications-Based Interventions Between Patients and Providers to Improve Cancer Control in the Primary Care Setting." Michigan Department of Community Health, contract #20011001, direct costs \$138,500. 5% effort (donated) for one year (funding date 10/1/00).
6. Co-Investigator, "Proactive Diabetes Case Management." Veterans Administration HSR&D IIR 970771, direct costs \$749,940. 5% effort for 3.5 years (funding date 9/1/98).
7. Co-Investigator, "Proactive Identification of Patients At-Risk for High Utilization: *Using the MCDR Telephone Interview*." University of Michigan

Faculty Group Practice Academic Venture Investment Fund VIF.FY99.065, direct costs \$178,917. 5% effort (donated) for 2 years (funding date 2/1/00).

8. Co-Investigator, "Evaluating a web-based tailored information and feedback program to improve colon cancer screening rates in the primary care setting: A randomized controlled trial" Michigan Department of Community Health, contract #20011001, direct costs \$240,000. Steven Katz, PI. 10% effort (donated) for 9 months (funding date 1/1/02; no cost-extension ongoing through 12/31/03).
9. Co-Investigator, "Implications of High Risk Health Behaviors on Work-Force Participation: Disability, Retirement, and Lost Productivity. Social Security Administration/Michigan Retirement Research Center grant 02-12, direct costs \$50,000. Caroline Richardson, PI. 10% effort for 1 year (funding date 1/1/2003).
10. Principal Investigator, "Modeling the health impacts of disparities in diabetes care". Commonwealth Fund; 20% effort; subcontract through David Nerentz, PhD, PI, Henry Ford Health System. Funding date 2/1/2004-7/30/2004.

CERTIFICATION AND LICENSURE

Medical Licensure: State of Michigan (expires 1/31/06)
 Federal DEA (expires 5/31/05)

Board Certification: Certified in Internal Medicine, 1995

MILITARY SERVICE

None

HONORS AND AWARDS

House Officer Research Award, Department of Internal Medicine, University of Michigan, 1994-1995

Outstanding Research Award, Midwest Society of General Internal Medicine, 1996

Top 10 abstract, University of Michigan Research Day, 1997

Outstanding Research Award, Midwest Society of General Internal Medicine, 1997

Chair, VA HSR&D Scientific Review and Evaluation Board, Implementation and Management Section

MEMBERSHIP AND OFFICES IN PROFESSIONAL SOCIETIES

American Medical Student Association, 1989-1992

Member, American College of Physicians, 1994-present

Society of General Internal Medicine, 1996-present

TEACHING ACTIVITIES

House officer mentor, Veterans Administration Primary Care Clinic, Ann Arbor, Michigan, 1996-present (rated in top quintile of faculty by residents, 2002-2004, received teaching bonus in 2003, 2004).

Management of Type 2 Diabetes lecture, University of Michigan Primary Care Conference, 1996.

Discussion leader, health policy sequence, second year medical students
Topic: physician supply issues. 1996-present.

Discussion leader, health policy sequence, second year medical students
Topic: guideline development and dissemination. 1996-present.

Discussion leader, health policy sequence, second year medical students.
Topic: The changing role of physicians under managed care. 1998-9, 1999-2000.

Discussion leader, second year medical students, endocrinology sequence. Topic: Evaluation of the medical literature, 1996-2002.

Discussion leader, "Critical Appraisal of the Medical Literature," fourth year medical students, 1996-present. Topic: guideline evaluation.

Discussion leader, problem-based learning ethics sequence, Introduction to the Patient, first year medical students, 1997-8

Attending physician, inpatient morning report, 1997-present..

Attending physician, intern report. 1999-present..

Attending physician, Chief of Medicine Rounds, 1998-present.

Attending rounds, inpatient medical service, Veterans Administration Medical Center, 1997-present..

Attending physician, residents' journal club, 1998-99, 1999-2000

Ambulatory care conference on critical appraisal and interpretation of the medical literature, 1997-8

Instructor, Robert Wood Johnson Clinical Scholars Summer Session, 1998-present

Noon conference, "Update in diabetes management", 1998, 2003.

University of Michigan Grand Rounds, 2000. "Risk stratification in medicine: application of clinical predictors of risk to clinical decision-making"

Noon conference, "Screening for cancer in primary care", 1999, 2001, 2003.

Evidence-based management of hypertension in type 2 diabetes. American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.

Evidence-based management of lipids in type 2 diabetes. American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.

Setting appropriate standards of care in type 2 diabetes. American College of Physicians. Philadelphia, PA, October 2003; October 2004.

MENTORING

Senior research project mentor, Erik-Jan Wamsteker, M.D., 1999. Cost-effectiveness of carotid endarterectomy in symptomatic patients with 50-69% stenoses

Senior research project mentor, Jim Lavelle, M.D., 2001-2. Predictors of positive blood cultures in patients admitted with community-acquired pneumonia.

Senior research project mentor, David Deguzman, M.D., 2002-3. Adherence and follow-up of fecal occult-blood testing for colorectal cancer screening.

Senior research project mentor, Gregory Bump, M.D., 2002-3. The impact of chronic diseases on self-management of type 2 diabetes.

Senior research project mentor, Ghazala Khan, M.D., 2003-4. Estimating the accuracy of echocardiography in predicting right ventricular systolic pressure.

Fellowship mentor, Peter Cram, MD, MBA, 2001-2003. Cost-effectiveness of external defibrillators; effects of celebrity spokespeople on health behaviors.

Fellowship mentor, Allison Rosen, MD, 2003-2004. Should Medicare cover ACE inhibitors for patients with diabetes? A cost-utility analysis.

Fellowship mentor, Paul Chan, MD, 2004-2005. Effectiveness and costs of catheter ablation of atrial fibrillation.

EXTRAMURAL INVITED PRESENTATIONS

Evidence-based management of hypertension in type 2 diabetes. American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.

Evidence-based management of lipids in type 2 diabetes. American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.

Economic issues in diabetes-related vision impairment. Centers for Disease Control, Economics of vision impairment: public health prevention opportunities. Atlanta GA, June 4, 2004.

Moderator, quality of care abstract session. SGIM Annual Meeting; Chicago, IL, May 2004.

Moderator, diabetes abstract session. VA HSR&D Annual Meeting; Washington, DC, March 2004.

The cost-effectiveness of screening for colorectal cancer. National Academy of Sciences, Institute of Medicine. Conference on Economic Modeling in Colorectal Cancer. Washington, DC, January 25-27, 2004.

Setting appropriate standards of care in type 2 diabetes. American College of Physicians. Philadelphia, PA, October 2003, October 2004.

Screening for colorectal cancer: an updated view of the literature. Mackinac Island Internal Medicine Update, Mackinac Island, MI, August 2003.

Prevention of cardiovascular disease in type 2 diabetes. Mackinac Island Internal Medicine Update, Mackinac Island, MI, August 2003.

Emerging paradigms in medicine: risk-stratifying screening for diabetic retinopathy. Mackinac Island Internal Medicine Update, Mackinac Island, MI, August 2003.

The cost-effectiveness of prevention of cardiovascular disease in type 2 diabetes. Common Problems in Office Practice symposium, Dearborn, MI. April 2003.

The impact of diabetes on work-force participation: results from a national sample. Social Security Retirement Research Consortium Annual Conference, National Press Club, Washington DC, June 2002.

Cost-utility of screening for diabetic retinopathy. Evidence-Base for a Disease Management Programme for Type 2 Diabetes. Frankfurt, Germany, January 2001. Sponsor: AOK-Bundesverband under the auspices of the European Diabetes Association (EASD).

Rates, predictors, and costs of disability in patients with type 2 diabetes. Michigan Retirement Research Council Health and Retirement Study seminar, January 2001.

The Importance of Patient Preferences when making treatment decisions in older patients. The Challenge of Diabetes Care in Older Adults, University of Michigan, September 2001.

Quality standards and the politics of medicine: How well-meaning people can cause blindness and death. Robert Wood Johnson Clinical Scholars, University of Michigan, April 2000.

Should we screen annually for diabetic retinopathy? Ophthalmology Grand Rounds, University of Michigan, April 2000.

OTHER PRESENTATIONS

None

COMMITTEE AND ADMINISTRATIVE SERVICES

Veterans Administration Hospital:

Chair, VA Ann Arbor Healthcare System Care Management Committee, 2003-present

University of Michigan Medical School:

Chair/Project team leader, University of Michigan type 2 diabetes guidelines development team, 1996-present

University of Michigan preventive care guidelines: Colorectal cancer screening, 1998-present

National/International

Panel member, National Institutes of Health consensus development conference on the management of celiac disease, June 28-30, 2004.

Chair, VA HSR&D Scientific Review and Evaluation Board, Implementation and Management Research section, 2004-2008.

Author, ACP PIER module for the management of type 2 diabetes, American College of Physicians, 1998-present

American College of Physicians evidence review and guidelines for the management of hypertension in type 2 diabetes, 2001-present

American College of Physicians evidence review and guidelines for the management of lipids in type 2 diabetes, 2002-present

Author, British Medical Journal Clinical Evidence, Management of hypertension in type 2 diabetes.

American Academy of Family Physicians and American Diabetes Association guidelines for glycemic control in type 2 diabetes, 1998-9

Assessing the Care of Vulnerable Elders, Type 2 Diabetes, RAND quality indicator development, 1999

Abstract review committee, VA HSR&D Annual Meeting, 2000, 2001, 2002, 2003

Abstract review committee, National Association of Inpatient Physicians Annual Meeting, 2002

Abstract review committee, VA QUERI Annual Meeting, 2003

Abstract review committee, VA Office of Research and Development Annual Meeting, 2003, 2004

Abstract review committee, Society for General Internal Medicine National Meeting, 2002, 2003, 2004

Chair, chronic disease workshop sub-committee, Society for General Internal Medicine National Meeting, 2004-5

Regional

Member, Greater Detroit Area Health Council Quality Forum Clinical Work Group, Diabetes sub-group, 1997-8.

Member, Daimler-Chrysler Evidence-Based Medicine in Action, diabetes practice guideline development committee, 1998.

PATENTS

None

BIBLIOGRAPHY

Peer-reviewed publications

1. Vijan S, Steven D, Herman WH, Funnell M, Standiford C. *Prevention, Treatment, and Counseling for the Prevention of Complications in Type II Diabetes. Putting Evidence into Practice*. Journal of General Internal Medicine. 1997; 12(9): 567-580.[abstracted in ACP Journal Club 1998; 128(2).]
2. Vijan S, Hofer TP, Hayward RA. *Estimated Benefits of Glycemic Control in Type 2 Diabetes*. Annals of Internal Medicine. 1997; 127(9): 788-795. [abstracted in Journal Watch 1997; 17 (23): 186-7]; [abstracted in American Journal of Managed Care 1998; 4(4): 480].
3. Goold SD, Vijan S. *Normative Issues in Cost Effectiveness Analysis*. Journal of Laboratory and Clinical Medicine. 1998; 132(5): 376-382.
4. Vijan S, Kent DM, Hayward RA. *Are randomized controlled trials sufficient evidence to guide clinical practice in type 2 diabetes mellitus?* Diabetologia. 2000;43: 125-30.
5. Vijan S, Hofer TP, Hayward RA. *A cost-utility analysis of screening intervals for diabetic retinopathy*. JAMA. 2000; 283(7): 889-896. [abstracted in the Detroit News; Reuters health; CBShealthwatch.com; Healthscout.com; WebMD.com]
6. Hofer TP, Vijan S, Hayward RA. *Effectiveness of screening for type 2 diabetes on prevention of microvascular complications*. International Journal of Technology Assessment in Health Care; 2000; 16(3):822-833
7. Vijan S. *Are we overvaluing performance measures?* Effective Clinical Practice. 2000;3(5): 247-249.
8. Valenstein M, Zeber J, Boehm K, Buttar A, Vijan S. *Should we screen for depression in primary care?. A cost-utility analysis*. Annals of Internal Medicine. 2001; 134:345-60.
9. Shekelle PG, Vijan S. *Quality indicators for the management of diabetes mellitus in vulnerable elders*. Annals of Internal Medicine. 2001; 135(8, part 2). Available at <http://www.acponline.org/sci-policy/acove/>
10. Kerr EA, Krein SL, Vijan S, Hayward RA. *Avoiding pitfalls in chronic disease quality measurement: A case for the next generation of technical quality measure*. American Journal of Managed Care. 2001; 7(11): 1033-1043.

11. Vijan S, Hwang E, Hofer TP, Hayward RA. *Which colon cancer screening test? A comparison of costs, effectiveness, and compliance.* American Journal of Medicine. 2001; 111: 593-601.
12. Nallamothu BK, Saint S, Ramsey S, Hofer TP, Vijan S, Eagle KA. *The role of hospital volume in coronary artery bypass grafting: Is more always better?* Journal of the American College of Cardiology. 2001; 38: 1923-30.
13. Langa KM, Vijan S, Blaum C, Kabeto MU, Chernew ME, Hayward RA, Katz SJ, Willis RJ, Fendrick AM. *The quantity and cost of informal caregiving for the elderly with diabetes: estimates from a nationally representative sample.* Journal of Gerontology. 2002; 57B: S177-S186.
14. Krein SL, Vijan S, Pogach LM, Hogan MM, Kerr EA. *Aspirin use and counseling about aspirin among patients with diabetes in VA.* Diabetes Care. 2002; 25: 965-970.
15. Kent DM, Griffith JL, Hayward RA, Vijan S, Beshansky J, Califf RM, Selker HP. *An independently-derived model for selecting patients likely to benefit from tissue plasminogen activator: Validating with GUSTO.* American Journal of Medicine. 2002; 113:104-111.
16. Vijan S, Hayward RA. *Treatment of hypertension in type 2 diabetes: Blood pressure goals, choice of agents, and setting priorities in diabetes care.* Annals of Internal Medicine. 2003; 138: 593-602. [abstracted by WebMD.com]
17. Cram P, Vijan S, Wolbrink A, Fendrick AM. *The impact of including passive benefits in cost-effectiveness analysis: The case of automated external defibrillators on commercial aircraft.* Value in Health. 2003; 6(4): 466-73.
18. Cram P, Inadomi J, Cowen ME, Carpenter D, Fendrick AM, Vijan S. *The impact of a healthy celebrity spokesperson on preventive health behavior: the Katie Couric effect.* Archives of Internal Medicine. 2003; 163(13): 1601-5.
19. Cram P, Vijan S, Fendrick AM. *Cost-effectiveness of automated external defibrillation deployment in selected public locations.* Journal of General Internal Medicine. 2003;18(9): 745-54.
20. Heisler M, Vijan S, Anderson RM, Ubel PA, Bernstein SJ, Hofer TP. *When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make?* Journal of General Internal Medicine. 2003; 18(11): 893-902.
21. Vijan S, Hayward RA. *Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus.* Annals of Internal Medicine. 2004; 140: 650-8. [abstracted in the New York Times; WebMD]

22. Langa KM, Valenstein MA, Fendrick AM, Kabeto MU, Vijan S. *Informal caregiving for older Americans with symptoms of depression*. American Journal of Psychiatry. 2004; 161: 857-863.
23. Krein SL, Klamerus ML, Vijan S, Lee J, Fitzgerald JT, Pawlow A, Reeves P, Hayward RA. *The effectiveness of proactive diabetes case management for high-risk patients*. American Journal of Medicine. 2004; 116(11):732-739.
24. Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky J, Selker HP. *Tissue Plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction*. Journal of Clinical Epidemiology 2004;57(8):843-852.
25. Vijan S, Inadomi J, Hayward RA, Hofer TP, Fendrick AM. *Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the US*. Alimentary Pharmaceuticals and Therapeutics. 2004; 20: 507-515.
26. Vijan S, Stuart N, Fitzgerald JT, Ronis DL, Hayward RA, Slater SS, Hofer TP. *Barriers to adherence with diet in type 2 diabetes*. Diabetic Medicine. 2004; in press.
27. Vijan S, Hayward RA, Langa KM. *The impact of diabetes on work-force participation: results from a national household sample*. Health Services Research. 2004;39(6 Pt 1):1653-70.
28. Nallamothu BK, Saint S, Hofer TP, Vijan S, Eagle KA, Bernstein SJ. *Hospital volume and outcome in coronary artery bypass grafting: A risk paradox?* Archives of Internal Medicine. 2004; in press.
29. Cram P, Vijan S, Katz D, Fendrick AM. *Cost-effectiveness of in-home automated external defibrillators for individuals at increased risk of sudden cardiac death*. Journal of General Internal Medicine. 2004; in press.

Manuscripts submitted for publication

30. Cho H, Mitrovich S, Dubay D, Hayward RA, Krein S, Vijan S. *Proactive case management of high-risk patients with type 2 diabetes by a clinical pharmacist: a randomized controlled trial*. (revision requested by *The American Journal of Managed Care*).
31. Hayward RA, Kent DM, Vijan S, Hofer TP. *Reporting clinical trial results to inform clinical practice: The need to assess benefits and harms for lower versus higher risk patients*. (submitted to *the American Journal of Medicine*).

32. Richardson C, Hanlon J, Mull H, Vijan S, Hayward RA, Wray L, Langa K. *The impact of poor health behaviors on work force related disability*. (submitted to *Medical Care*)
33. Vijan S, Hayward RA, Ronis DL, Hofer TP. *Patient views of the burden of diabetes therapy: implications for adherence and the design of effective treatment regimens* (revision requested by *the Journal of General Internal Medicine*).
34. Chung KC, Davis EN, Kotsis SV, Lau FH, Vijan S. *Cost-utility analysis of cast immobilization versus open reduction and internal fixation for acute non-displaced mid-waist scaphoid fractures* (submitted to *The Journal of Bone and Joint Surgery*).
35. Vijan S, Hwang I, Choi JR, Napierkowski J, Koff J, Inadomi J, Pickhardt P, Wong R. *The cost-effectiveness of virtual colonoscopy in screening for colorectal cancer* (revision requested by *Annals of Internal Medicine*).
36. Rosen AB, Hamel MB, Weinstein MC, Vijan S. *Cost-effectiveness of Medicare first-dollar coverage of ACE inhibitors for beneficiaries with diabetes* (revision requested by *Journal of the American Medical Association*).
37. Heisler M, Piette JD, Spencer M, Kieffer E, Vijan S. *The relationship between knowledge of recent hemoglobin a1c values and diabetes care understanding and self-management* (submitted to *the Journal of General Internal Medicine*).
38. Chan P, Oral H, Vijan S. *Cost-effectiveness of left atrial catheter ablation of atrial fibrillation* (submitted to *Annals of Internal Medicine*).

Non-peer reviewed publications

Is optimal glucose control worthwhile? Patient Care 1998; 32(3): 23-4.

Hayward RA, Vijan S. *Diabetes Care Priorities: Preventing Cardiovascular Complications*. VA Practice Matters, May 2000, Vol. 5, Issue I.

Vijan S. The use of statin therapy in type 2 diabetes. *Diabetes Self-Management*; September/October 2004, p. 65.

Book chapters/Web-based educational modules

1. Vijan S. *Diagnosis and management of type 2 diabetes*. American College of Physician PIER modules. American College of Physicians; published in web form, 2002. Available at <http://pier.acponline.org>

2. Vijan S. The cost-utility of screening for diabetic retinopathy. In: Stichwort: Diabetes. Documentation of an International Symposium. Bonn: mbH & Co, 2002. Pages 37-43.

Abstracts (partial listing)

1. Vijan S, Hofer TP, Hayward RA. *The benefits of glycemic control in type diabetes.*
2. Vijan S, Hwang E, Hofer TP, Hayward RA. *Screening strategies for colon cancer: flexible sigmoidoscopy and fecal occult-blood testing versus colonoscopic screening*
3. Vijan S, Hofer TP, Hayward RA. *Screening intervals for diabetic retinopathy: are current guidelines justifiable?*
4. Ronis, DL, Vijan S, Hayward RA, Phillips CV, Hofer TP. *Diabetes patients' views of treatments.*
5. Stuart N, Vijan S, Ronis D, Hayward RA. *Patient preferences for the care of diabetes.*
6. Wamsteker E-J, Vijan S. *The cost-effectiveness of carotid endarterectomy inpatients with symptomatic 50 to 69% stenoses*
7. Vijan S, Zeber J, Valenstein M. *Should we screen for depression in primary care? A cost-utility analysis.*
8. Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky J, Selker HP. *Effectiveness and cost-effectiveness of t-PA relative to streptokinase in 921 patients treated with thrombolytic therapy: potential clinical and economic benefits of targeting therapy.*
9. Kent DM, Griffith JL, Hayward RA, Vijan S, Beshansky J, Califf RM, Selker HP. *An independently-derived model for selecting patients likely to benefit from tissue plasminogen activator: Validating with GUSTO.*
10. Vijan S, Fitzgerald JT, Stuart N. *Patient attitudes towards diet in type 2 diabetes.* Diabetes 2000;49;A446.
11. Fitzgerald JT, Vijan S, Stuart N. *Insulin therapy and patient attitudes at two VA Centers.* Diabetes 2000;49;A445.
12. Vijan S, Langa K, Stuart N, Hayward RA. *Racial variation in disability in type 2 diabetes.*

13. Vijan S, Langa K, Stuart N, Hayward RA. *Rates, causes, and costs of disability in patients with type 2 diabetes: results from a national sample.*
14. Zeber J, Vijan S, Valenstein M. *Cost-utility of depression screening: usual care versus collaborative treatment.*
15. Krein SL, Klamerus ML, Vijan S, Pawlow A, Reeves P, Hayward RA. *Proactive diabetes case management: expectation versus reality.*
16. Davis JA, Krein SL, Kerr EA, Vijan S, Hayward RA. *Evaluating a VISN-wide multi-faceted intervention to improve diabetes care.*
17. Vijan S, Inadomi J, Fendrick AM, Hofer TP, Hayward RA. *The impact of colorectal cancer screening recommendations on colonoscopy demand.*